Hope through science.
Healing through cells.
Meet DestroCell — a scientifically validated, placenta-derived cell therapy designed to calm dangerous inflammation, protect delicate tissues and restore hope where conventional treatments have failed.
DestroCell®
Placenta-derived decidua stromal cells
A new frontier in regenerative medicine
Taskin BioRegeneration is a pioneering Iranian biotechnology company specialising in advanced cell and gene therapies. Our mission is to deliver transformative, life-saving treatments for serious conditions — and to make them accessible and affordable, especially in regions that need them most.
Built on a strong foundation of research and global collaboration, our flagship therapy DestroCell exemplifies our commitment to regenerating health, improving outcomes and restoring hope to patients with limited options.
What is DestroCell?
DestroCell is a special type of stromal cell found in the placenta — the protective environment that naturally keeps inflammation low during pregnancy. This unique biology gives it an extraordinary ability to regulate the immune system and protect blood vessels. Collected safely after normal births with full donor consent and screening, the cells are stored frozen — ready the moment they are needed.
The body’s own “immune moderators”
Calms overactive immunity
Soothes overactive immune cells while boosting protective regulatory cells.
Reduces harmful inflammation
Lowers damaging inflammatory chemicals (cytokines) and increases healing signals.
Switches cells to repair mode
Shifts immune cells called macrophages from a destructive mode into a healing one.
Protects blood vessels
Shields the lining of small blood vessels, preventing leakage and tissue damage.
Releases repair factors
Secretes natural repair factors that help vital organs recover and regenerate.
Ready-to-use
Stored frozen and thawed the moment it is needed — critical for acute, life-threatening illness.
No matching required
Allogeneic donor cells work without HLA matching to the patient.
Acts in many ways at once
Targets both immune over-reaction and blood-vessel damage simultaneously.
A stronger source
Placenta-derived decidua stromal cells show broader effects than bone-marrow or fat-derived cells.
New hope for children
with autism
DestroCell offers a scientifically backed cellular approach to support children with autism — targeting the biological root of symptoms, not just behaviour.
Reduces neuroinflammation
Supports brain repair & communication pathways
Improves social behaviour & eye contact
Conditions DestroCell may help
In each case, DestroCell aims to slow damaging inflammation, protect vital organs and create the conditions for recovery.
Autism Spectrum Disorder
A cellular approach targeting the biological roots of symptoms — not just behaviour.
Graft-versus-Host Disease
The approved flagship indication, including steroid-refractory acute GvHD.
Acute Respiratory Distress (ARDS)
Calms the cytokine storm and supports alveolar barrier restoration.
Sepsis & Septic Shock
Helps restore systemic immune balance during overwhelming inflammation.
Multiple Sclerosis (MS)
Modulates inflammation at sites of injury to support neuro-immune balance.
Crohn's Disease
Re-balances gut immunity and creates conditions for epithelial repair.
Autoimmune Flare-Ups
Dampens harmful immune over-reaction in severe autoimmune episodes.
Cytokine Release Syndrome
Acts fast and in many ways at once when time is everything.
Science you can trust
DestroCell is built on rigorous science, international recognition and a strong record of safety.
US FDA — IND Clearance
Cleared by the US Food and Drug Administration to conduct advanced clinical trials.
Orphan Drug Designation
Awarded by both the US FDA and the European Medicines Agency for severe, rare conditions.
Iran FDA Approved
The first Iranian allogeneic cell therapy for GvHD, listed in the Iranian Pharmacopeia.
GMP-Certified Manufacturing
Every batch produced in ultra-clean laboratories under strict Good Manufacturing Practice.
50+ Scientific Publications
Over fifty peer-reviewed papers documenting the research, safety and efficacy.
Protected by US Patent
A unique, patented placenta-derived cell technology — a genuine first in its field.
Showcased at the International Private Hospitals Congress & Exhibition 2025, Tehran.
Your treatment journey
A clear, supported path — from your first consultation to follow-up care back home.
Careful evaluation
Your medical history, tests and current condition are reviewed to confirm DestroCell therapy is right for you.
A clear plan
You receive a simple explanation of how the therapy works, the expected benefits and any possible risks — then decide together.
Infusion
On treatment day, the ready-to-use cells are thawed and infused through a vein over about 30–60 minutes, with close monitoring.
Support & follow-up
Scheduled check-ins track your progress, adjust care if needed, and answer every question along the way.
Care built on confidence and transparency
Most patients tolerate DestroCell therapy well. Common effects such as mild fever or chills pass quickly, and serious reactions are rare — thanks to careful donor screening, GMP manufacturing and close medical supervision.
Realistic expectations: we cannot promise a cure, but we promise transparency, safety and our very best effort. Every patient is always told the exact status of the therapy before starting.
Only mild, transient side effects reported
Safety & potency tested before release
Monitored until the moment of infusion
Full donor consent & screening